3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Conditions
Lymphoma, T-Cell, Peripheral
2
Hodgkin Disease
2
Recurrence
1
Interventions
Cyclophosphamide
23
Prednisone
16
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
14
Vincristine
11
Doxorubicin
11
Etoposide
9
fludarabine phosphate
8
Whole-Body Irradiation
8
Mycophenolic Acid
7
Lenalidomide
7
Peripheral Blood Stem Cell Transplantation
6
Gemcitabine
6
Brentuximab Vedotin
6
Azacitidine
6
Alemtuzumab
6
Cyclosporine
5
Bortezomib
5
romidepsin
4
fludarabine
4
Tacrolimus
4
Rituximab
4
Methotrexate
4
Granulocyte Colony-Stimulating Factor
4
Cytarabine
4
pembrolizumab
3
denileukin diftitox
3
Transplantation
3
Dexamethasone
3
Carmustine
3
Busulfan
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Lymphoma, T-Cell, Peripheral
×
AFM13
×
Clear all
NCT05883449
2025-08-20
LuminICE-203
Affimed GmbH
Phase 2
Terminated
25 enrolled
21 charts
NCT04101331
2024-11-05
REDIRECT
Affimed GmbH
Phase 2
Completed
108 enrolled
24 charts